Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer

Published:2018-01-09 Issue:2 Volume:35 Page:
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Mohammad Afroz S.,Griffith Jessica I.,Adkins Chris E.,Shah Neal,Sechrest Emily,Dolan Emma L.,Terrell-Hall Tori B.,Hendriks Bart S.,Lee Helen,Lockman Paul R.

Funder

National Cancer Institute

National Institute of General Medical Sciences

Merrimack Pharmaceuticals, Inc and Ipsen Biopharmaceuticals, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

http://link.springer.com/article/10.1007/s11095-017-2278-0/fulltext.html

Reference52 articles.

1. Society AC. Breast cancer facts & figures 2015–2016. 2015.

2. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–25.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

4. H. Nitta BD Kelly, C. Alfred, S. Jewell, P. Banks, E. Dennis, T.M. Grogan. The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int. 2016.

5. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides;ACS Nano;2024-08-12

2. CNS delivery of targeted protein degraders;Journal of Controlled Release;2024-08

3. PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice;Scientific Reports;2024-06-19

4. 3D brain image based tumor classification using ensemble of reinforcement transfer-based belief neural networks;Multimedia Tools and Applications;2024-06-13

5. Nanoparticle drug delivery system for the treatment of brain tumors: Breaching the blood–brain barrier;Acta Pharmaceutica Sinica B;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3